BHCM
GTHX

Brevan Howard Capital Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Brevan Howard Capital Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-47,545
Closed -$205K – 1466
2024
Q1 		$205K Buy
+47,545
New +$166K ﹤0.01% 798

Other funds holding GTHX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Brevan Howard Capital Management's GTHX Position: Q2 2024 in Review

Brevan Howard Capital Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 47,545 shares — an estimated $205K sold.

Brevan Howard Capital Management first reported a position in GTHX in Q1 2024 and held it in 1 quarter. The position peaked at $205K in Q1 2024. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.

  • Brevan Howard Capital Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 47,545 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $205K.
  • Brevan Howard Capital Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2024 and held it in 1 quarter.
  • Brevan Howard Capital Management's G1 Therapeutics, Inc. Common Stock position peaked at $205K in Q1 2024.
  • 88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Brevan Howard Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.